Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

(2014) JE Lake et al.   HIV MEDICINE

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

(2014) Marie-Anne Vandenhende et al.   PLoS One

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

(2013) Antonella d’Arminio Monforte et al.   AIDS

Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients

(2013) A Jansen et al.   HIV MEDICINE

Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function

(2013) Samir K. Gupta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy

(2013) Erika F. Silva et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

(2013) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review

(2013) Clay Bavinger et al.   PLoS One

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy

(2013) Marc Noguera-Julian et al.   Virology Journal

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

(2013) Amit C Achhra et al.   AIDS Research and Therapy

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

(2012) Esteban Martínez et al.   AIDS

Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population

(2012) Alison J. Rodger et al.   AIDS

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

(2012) Michael J. Kozal et al.   HIV CLINICAL TRIALS

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

(2012) Dianne Carey et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing

(2012) Daniele Armenia et al.   JOURNAL OF INFECTIOUS DISEASES

Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA

(2012) Yu Ming Paul Lam et al.   PLoS One

Switching between raltegravir resistance pathways analyzed by deep sequencing

(2011) Rithun Mukherjee et al.   AIDS

Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study

(2011) Nico Reinsch et al.   European Journal of Preventive Cardiology

HIV transmission and high rates of late diagnoses among adults aged 50 years and over

(2010) Ruth D Smith et al.   AIDS

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

(2010) Sylvie Lang et al.   AIDS

Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers

(2010) M. Neely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

(2010) Li Zhu et al.   ANTIVIRAL THERAPY

Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected PatientsA Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4Antiretroviral Drugs, Risk of MI, and HIV

(2010) Sylvie Lang   ARCHIVES OF INTERNAL MEDICINE

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir

(2010) Rumi Minami et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Unknown

(2010)   JOURNAL OF INFECTIOUS DISEASES

Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients

(2010) Dario Cattaneo et al.   THERAPEUTIC DRUG MONITORING

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study

(2009) S. Di Giambenedetto et al.   INFECTION

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

(2008) Marian Iwamoto et al.   CLINICAL INFECTIOUS DISEASES

Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial

(2008) A J Flammer et al.   HEART